

Press release

First results from the ANRS Prevenir study: 1,500 participants, 0 infection

One year after its launch, the ANRS Prevenir study is delivering its initial findings. This study is coordinated by Professor Jean Michel Molina and funded by the ANRS in partnership with the French non-profit community organisation, AIDES. Among the 1,435 participants already enrolled in the Paris region (Île-de-France), these results confirm the efficacy and safety of daily or on-demand pre-exposure prophylaxis (PrEP)¹. These results will be presented this Wednesday, 25 July at the 22nd international conference on HIV/AIDS (AIDS 2018), being held in Amsterdam from 23 to 27 July 2018.

The ANRS Prevenir study, launched in May 2017 by Pr Jean-Michel Molina (Hôpital Saint-Louis, AP-HP), Jade Ghosn (Hôpital Hôtel Dieu, AP-HP) and Daniela Rojas-Castro (AIDES association), aims to assess the impact of PrEP on the HIV/AIDS epidemic in the Paris region (Île-de-France). It also seeks to assess individual community-based support, as well as the prevention and treatment of other sexually transmitted infections.

The results reported today concern the first 1,435 HIV-negative participants at high risk of becoming infected with HIV who were recruited between 3rd May 2017 and 1st May 2018. At present, these are mainly men who have sex with men. *“In the future, we want to enrol participants from other populations, such as transgender and heterosexual men and women at high risk of HIV infection”* states Prof. Jean Michel Molina.

Among the participants, 44% are taking PrEP on a daily basis and 53% are using it on-demand during periods of sexual activity (this strategy has been proven effective by the ANRS IPERGAY trial and endorsed by national and European recommendations). To date, no cases of HIV infection have been observed in either those taking daily PrEP or those who chose the on-demand dosage regimen. According to Professor Molina, *“these results confirm that PrEP is highly effective since they have been obtained in people at high risk of HIV infection”*.

These initial findings presented at the AIDS 2018 conference in Amsterdam also support the safety of PrEP. Indeed, PrEP (TDF/FTC) has not been discontinued due to drug-related adverse events.

For more information:

Website: <http://prevenir.anrs.fr/>

¹ PrEP: Pre-exposure prophylaxis, or PrEP, is an antiretroviral treatment to prevent HIV infection

Facebook: @ANRSprevenir
Twitter: @anrs_prevenir

The main aim of the ANRS PREVENIR (Prevention of HIV in the Paris region (Île-de-France)) study is to assess a comprehensive HIV prevention strategy for people who do not have HIV but who are at high risk of acquiring it in the Paris region (Île-de-France). This strategy includes intensified screening programmes, the provision of support, early treatment of HIV infections and pre-exposure prophylaxis treatment (PrEP). Launched in May 2017, this study support by the Sidaction, la region Ile-de-France and la mairie de paris, is placed under the joint responsibility of Professor Jean- Michel Molina (Hôpital Saint-Louis, AP-HP) Principal investigator, Dr Jade Ghosn (Hôpital Hotel-Dieu, AP-HP) and Ms Daniela Rojas-Castro (Association AIDES), co-investigators. ANRS PREVENIR plans to enrol 3,000 participants by 2019 who will be monitored until 2020.

The ANRS is a French agency that drives and coordinates research on HIV/AIDS and viral hepatitis. The ANRS seeks to mobilise, assess, coordinate and fund research projects irrespective of the specific scientific field (this includes basic, clinical, public health and vaccine research). The ANRS brings together researchers of all disciplines both in France and abroad. It has an annual budget of approximately 50 million euros, the majority of which is allocated by the French Ministries of Research and Health. In 2012, the ANRS became an independent agency of Inserm. In total, the ANRS has funded more than 500 research projects and grants.

Sources:

Incidence of HIV-infection in the ANRS Prevenir Study in Paris region with Daily or On-Demand PrEP with TDF/FTC

J.-M. Molina , J. Ghosn , L. Béniguel , D. Rojas-Castro , M. Algarte-Genin , G. Pialoux , C. Delaugerre , Y. Yazdanpanah , C. Katlama , C. Ségouin , S. Morel , C. Pintado , B. Loze , S. Le Mestre , S. Gibowski , V. Doré , L. Assoumou , B. Spire , D. Costagliola , Prevenir ANRS study group

University of Paris Diderot, Sorbonne Paris Cité, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, Paris Descartes University, Sorbonne-Paris-Cité, Hotel-Dieu Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, INSERM, Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France, Coalition PLUS, Pantin, France, Sorbonne Université, Tenon Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, INSERM, University of Paris Diderot, Sorbonne Paris Cité, IAME (Infection, Antimicrobials, Modelling, Evolution), Bichat Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, INSERM, Sorbonne Université, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, Lariboisière Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, AIDES, Pantin, France, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, ANRS, France REcherche Nord & sud Sida-hiv Hépatites, Agence autonome de l'INSERM, Paris, France, Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l'Information Médicale, ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France

📍 Scientific contact:

Jean Michel Molina

jean-michel.molina@aphp.fr

📍 ANRS Press contacts :

Séverine Ciancia

Nolwenn Plusquellec

information@anrs.fr

📍 AP-HP Press contact:

Juliette Hardy – Marine Leroy

+33 (0)1 40 27 37 22

service.presse@aphp.fr

www.anrs.fr

